Market Closed -
Bombay S.E.
11:21:39 26/04/2024 BST
5-day change
1st Jan Change
1,616
INR
+1.31%
+4.45%
+22.13%
Sales 2024 *
199B
2.38B
191B
Sales 2025 *
217B
2.61B
209B
Capitalization
736B
8.83B
707B
Net income 2024 *
19.85B
238M
19.06B
Net income 2025 *
23.23B
279M
22.3B
EV / Sales 2024 *
3.83
x
Net Debt
2024
*
24.9B
299M
23.91B
Net Debt
2025
*
9.52B
114M
9.14B
EV / Sales 2025 *
3.43
x P/E ratio 2024 *
37.4
x
P/E ratio 2025 *
32
x
Employees
20,933
Yield 2024 *
0.44%
Yield 2025 *
0.53%
Free-Float
52.83%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
EXCLUSIVA-Eli Lilly podría lanzar un fármaco contra la obesidad en India el próximo año: presidente ejecutivo
02-28
Wall Street fait relâche
01-15
En Direct des Marchés : ArcelorMittal, Airbus, Atos, Casino, Deutsche Bank, SoftwareOne, Baidu...
01-15
EN DIRECTO DESDE LOS MERCADOS: ArcelorMittal, Airbus, Apple, FedEx, EQT, Citigroup, Deutsche Bank, SoftwareOne, Baidu...
01-15
Accenture : accompagne la transformation de Lupin Limited
20/06/22
More news 1 day +1.31%
1 week +4.45%
Current month -0.12%
1 month +0.21%
3 months +11.14%
6 months +41.55%
Current year +22.13%
More quotes
Managers
Title Age Since
Chief Executive Officer
56
31/12/96
President
-
-
Director of Finance/CFO
59
12/08/07
Members of the board
Title Age Since
Director/Board Member
74
26/10/15
Director/Board Member
69
27/01/21
Director/Board Member
50
31/12/95
More insiders
Date
Price
Change
Volume
26/04/24
1,616
+1.31%
42,605
25/04/24
1,595
+0.94%
13,663
24/04/24
1,580
-0.03%
43,612
23/04/24
1,581
-1.63%
15,690
22/04/24
1,607
+3.86%
29,348
Delayed Quote
Bombay S.E., April 26, 2024 at 11:21 am
More quotes
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas:
- design and production of generic and brand-name formulations;
- production of active pharmaceutical ingredients.
At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil.
Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
More about the company
Last Close Price
1,616
INR
Average target price
1,516
INR
Spread / Average Target
-6.18%
Consensus
1st Jan change
Capi.
+22.13% 8.83B +25.83% 661B +27.00% 566B -6.76% 352B +20.34% 332B +3.00% 283B +13.09% 231B +5.46% 200B -9.61% 195B -6.26% 145B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1